In a move that is likely to bring relief to a huge number of breast cancer patients, Alkem Oncology recently announced the launch of the breast cancer drug, Palbociclib under the brand name, Palbo.
Palbo which contains Palbociclib, is recommended by the National Comprehensive Cancer Network (NCCN-2022) as a first-line treatment for individuals with metastatic breast cancer who have hormone receptor positive (HR +)/human epidermal growth factor receptor 2-negative (HER2-) status. It is approved by the USFDA, EMA and CDSCO when used in conjunction with either Aromatase Inhibitor (AI) or Fulvestrant. Backed by in-house manufacturing, the launch of Palbo by Alkem endeavors to ensure the accessibility and affordability of a novel life-saving cancer drug for Indian breast cancer patients.
Palbo comes in capsule form in multiple dose strengths with varied pricing ranges, including 125mg at INR 6125/- for 21 capsules, 100mg at Rs. 6062/-, and 75mg at MRP Rs. 6000/- for 21 capsules. Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer which helps in inhibiting Cancer Cell growth.
“While this breast cancer drug is highly useful to patients, its reach in India is limited partly due to the high costs attached to the drug. We have now launched an affordable drug version backed by in-house production. We aim to make it easily accessible to the Indian population, ensuring availability at every Pincode in the country,” company spokesperson said.
Palbociclib along with AI & SERD (Fulvestrant) has been shown to significantly improve longevity among breast cancer patients, slow down the progression of disease, reduce cancer-related symptoms. Palbociclib capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant.
Alkem is a leading Indian global pharmaceutical company that manufactures & markets Biosimilars & Pharmaceutical formulations in India & across the globe.